Published in Cancer Weekly, October 23rd, 1995
The collaboration will provide up to ten million pounds sterling ($15.8 million) in milestone payments to Celltech, subject to satisfactory clinical progress, which will in addition receive royalties on worldwide sales of products that arise from the collaboration.
The ability of tumors to grow and spread in the body depends upon their capacity to form new blood vessels and to digest surrounding tissues. Gelatinase, a member of the matrix metalloproteinase class of enzymes, has been implicated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.